Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

9.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket
Gainers NeoGames S.A. (NASDAQ: NGMS) shares surged 121% to $28.38 in pre-market trading as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! 
Via InvestorPlace
Recap: Aligos Therapeutics Q1 Earnings
 
Via Benzinga
Aligos Therapeutics Earnings Preview
 
Via Benzinga
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
A Preview Of Aligos Therapeutics's Earnings
 
Via Benzinga
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
 
Via Benzinga
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
 
Via Benzinga
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Where Aligos Therapeutics Stands With Analysts
Within the last quarter, Aligos Therapeutics (NASDAQ:ALGS) has observed the following analyst ratings: 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate
Aligos Therapeutics Inc (NASDAQ: ALGS) has  
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00. Shares of Aligos Therapeutics are trading up 0.0% over... 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
 
Via Benzinga
Aligos Therapeutics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q2, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $3.69 million. Earnings were up 44.06%, but Aligos Therapeutics still reported an overall loss of $19.92... 
Via Benzinga
Aligos Therapeutics Earnings Preview
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study
Aligos Therapeutics, Inc. (NASDAQ: ALGS) has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201. 
Via Benzinga
Aligos Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Upgrades 
Via Benzinga
Preview: Aligos Therapeutics's Earnings
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022
Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
SVB Leerink cut the price target on TCR2 Therapeutics Inc. (NASDAQ: TCRR) from $7 to $3. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday. 
Via Benzinga
Recap: Aligos Therapeutics Q4 Earnings
Aligos Therapeutics (NASDAQ:ALGS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.